Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

Benzinga · 2d ago
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.